“ If Europe can consistently bring that expertise to bear at the right time, it will increase the likelihood of success and position companies for more sustainable… ”
In Conversation
Urs Indermühle – Managing Partner Consulting Switzerland (Non FS) and Life Sciences Sector Leader Europe West, EY
“ The combination of Switzerland's pharmaceutical excellence, our global connectivity, and advanced AI capabilities positions us to lead industry transformation initiatives that will define the next decade… ”
“ The ophthalmology sector has experienced significant capital influx following the emergence of several blockbuster treatments that demonstrated substantial commercial viability. ”
“ The healthcare sector's industrial vitality directly supports our broader healthcare system objectives, creating a virtuous cycle that benefits both economic competitiveness and public health outcomes. ”
“ The Île-de-France region houses 40-50 percent of France's academic research capacity and industrial development capabilities, creating an exceptionally dense innovation landscape that requires strategic navigation. ”
“ Our strategic approach emphasises local commercial partnerships to maximise regional value creation ”
“ Culture outweighs strategy in sustaining long-term success ”
Kasper Møller – Chief Technical Officer and Executive Vice President, Europe & Japan Regions, AGC Biologics
“ Copenhagen’s role is not just about offering capacity, but about providing unique capabilities backed by the experience, resilience, and reliability that AGC Biologics has built over… ”
“ Academic institutions are increasingly responsible for the most challenging aspects of drug development—target identification, mechanism validation, and early-stage clinical translation—while pharmaceutical companies focus on later-stage clinical… ”
“ Oculis represents a global biopharma enterprise focused exclusively on ophthalmology and neuro-ophthalmology, with our organizational DNA centred on visionary innovation. ”
“ Bold measures to enhance France and Europe’s industrial competitiveness have never been more critical ”
Andrea Alimonti – Professor at the Department of Health Sciences and Technology, Institute of Oncology Research (IOR)
“ Our goal is to accelerate the journey from fundamental research to real-world clinical applications, particularly in oncology, where time can quite literally mean lives. ”